Global Payments Stock Jumps On Reports Of Elliott Management Stake
The stock of Global Payments (GPN) is up 6% on media reports that activist investor Elliott Investment Management has built a sizable stake in the company. Global Payments is a leading financial technology company that provides payment technology and services to merchants and consumers. The Financial Times was first to report that Elliott Management, one of the world’s largest and most aggressive activist funds, has built a stake in Global Payments. The exact size of Elliott’s stake in Global Payments isn’t known, but the activist investment firm has a reputation for pushing companies to change in ways that reward shareholders.Elliott Management has targeted Global Payments after its stock dropped 55% over the last five years, including a 30% decline since the start of this year. Global Payments’ stock has failed to recover from a big drop this past April after the company bought rival Worldpay for $24 billion U.S.The acquisition expanded Global Payments’ reach but grew its debt load and created difficulties in integrating the two businesses. Before the Worldpay purchase, Global Payments had been divesting various business units and buying back its own stock.Neither Global Payments or Elliott Management have commented publicly on the media reports or relationship between the two firms. GPN stock is currently trading at $82.25 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


